Recommendations for the study of monoclonal gammopathies in the clinical laboratory. A consensus of the Spanish Society of Laboratory Medicine and the Spanish Society of Hematology and Hemotherapy. Part III: Clinical and analytical recommendations fo
Monoclonal gammopathies (MGs) represent a diverse group of plasma cell disorders that range from asymptomatic premalignant conditions to aggressive malignancies such as multiple myeloma (MM). Mass spectrometry (MS) based serum analysis offers a non-invasive, highly sensitive alternative to conventional techniques for identifying and quantifying M-proteins. It enables more precise assessment of treatment response and residual disease, particularly in patients with suspected complete response (CR), those not eligible for bone marrow procedures, or those treated with monoclonal antibodies that may interfere with standard assays. This guideline document, endorsed by the Spanish Society of Laboratory Medicine (SEMEDLAB) and the Spanish Society of Hematology (SEHH), provides comprehensive recommendations for the clinical and analytical application of MS in the detection and monitoring of M-proteins in patients with MGs. The document outlines optimal use of MS at diagnosis, during follow-up, and in reporting practices, with a focus on standardized implementation, interpretative criteria, and clinical decision-making support.
Authors
- Cristina Agulló
- Elena Cruz-Iglesias
- Jesús F. San Miguel (ORCID: https://orcid.org/0000-0002-9183-4857)
- María‐Victoria Mateos (ORCID: https://orcid.org/0000-0003-2390-1218)
- Javier de la Rubia (ORCID: https://orcid.org/0000-0002-8354-768X)
- Joaquín Martínez‐López (ORCID: https://orcid.org/0000-0001-7908-0063)
- Marta Iglesias (ORCID: https://orcid.org/0000-0001-7373-4927)
- A Fontán
- S. Castro (ORCID: https://orcid.org/0000-0002-3814-9420)
- Noemí Puig (ORCID: https://orcid.org/0000-0001-7535-3861)
- Nerea Varo (ORCID: https://orcid.org/0000-0002-2362-9472)
- Ramón García‐Sánz (ORCID: https://orcid.org/0000-0003-4120-2787)
- María Isidoro‐García (ORCID: https://orcid.org/0000-0002-9013-9422)
- Carmen Mugueta (ORCID: https://orcid.org/0000-0003-2800-4735)
- Juan Flores‐Montero (ORCID: https://orcid.org/0000-0002-1119-4387)
- María Ortiz-Espejo
- David Pérez-Surribas
- Bruno Paiva
- María Cruz Cárdenas
- Rosa Pello (ORCID: https://orcid.org/0009-0004-6894-2755)
Institutions
- Universidad de Salamanca (ES)
- Hospital General Universitario Gregorio Marañón (ES)
- Hospital Clínico San Carlos (ES)
- Research Institute Hospital 12 de Octubre (ES)
- Hospital de Basurto (ES)
- University of Andorra (AD)
- Marqués de Valdecilla University Hospital (ES)
- Sociedad Española de Medicina de Familia y Comunitaria (ES)
- Navarre Institute of Health Research (ES)
- Hospital Universitario Miguel Servet (ES)
- Centro de Investigación Biomédica en Red (ES)
- Instituto de Investigación Biomédica de Salamanca (ES)
- Clinica Universidad de Navarra (ES)
- Centro de Investigación del Cáncer (ES)
- Spanish Society of Hematology and Hemotherapy (ES)
- Research Network (United States) (US)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Instituto de Investigación Sanitaria La Fe (ES)
Publication Details
- Journal
- Clinical Chemistry and Laboratory Medicine (CCLM)
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1515/cclm-2025-1056
- Citations
- 1
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77